DUALITY ADVISERS, LP - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 182 filers reported holding BRIDGEBIO PHARMA INC in Q1 2022. The put-call ratio across all filers is 0.50 and the average weighting 0.3%.

Quarter-by-quarter ownership
DUALITY ADVISERS, LP ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q3 2023$1,296,244
+86.3%
49,156
+17.1%
0.16%
+98.7%
Q1 2023$695,896
-80.7%
41,972
-80.6%
0.08%
-79.8%
Q4 2021$3,607,000
+114.1%
216,254
+501.4%
0.39%
+203.1%
Q3 2021$1,685,000
+7.2%
35,956
+39.5%
0.13%
-7.9%
Q2 2021$1,572,00025,7820.14%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q1 2022
NameSharesValueWeighting ↓
Aisling Capital Management LP 6,068,125$160,016,45665.94%
Kohlberg Kravis Roberts & Co. L.P. 31,060,971$819,077,80528.79%
Cormorant Asset Management, LP 4,662,530$122,950,9167.17%
Frazier Life Sciences Management, L.P. 2,725,949$71,883,2754.77%
Octagon Capital Advisors LP 971,639$25,622,1203.94%
M28 Capital Management LP 121,200$3,196,0443.66%
VIKING GLOBAL INVESTORS LP 25,120,991$662,440,5332.69%
BOONE CAPITAL MANAGEMENT LLC 313,381$8,263,8572.61%
Fernwood Investment Management, LLC 235,620$6,213,2992.23%
SOUTHPORT MANAGEMENT, L.L.C. 15,000$395,5502.15%
View complete list of BRIDGEBIO PHARMA INC shareholders